CSL Limited (ASX: CSL)
The first blue chip ASX share to consider is CSL. It is one of the world’s leading biotechnology companies, comprising two businesses – CSL Behring and Seqirus. CSL Behring is the number one player in a global plasma therapies industry worth a massive US$30 billion per year. Whereas Seqirus is the number two player in the US$6 billion global influenza vaccines industry. CSL has been tipped for solid long term growth thanks to increasing demand for its therapies and its lucrative R&D pipeline.
UBS is positive on CSL. It currently has a buy rating and $330.00 price target on its shares.
CSL Limited (ASX: CSL)The first blue chip ASX share to consider...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$277.63 |
Change
-0.270(0.10%) |
Mkt cap ! $134.1B | |||
| Open | High | Low | Value | Volume |
| $277.94 | $279.11 | $276.35 | $217.1M | 783.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 315 | $277.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $277.63 | 49 | 1 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$277.63 |
Change
-0.270 ( 0.34 %) |
||||
| Open | High | Low | Volume | ||
| $278.97 | $278.97 | $276.36 | 25608 | ||
| Last updated 16.10pm 21/05/2024 ? | |||||
| CSL (ASX) Chart |